Curasight A/S announced preclinical data demonstrating preclinical proof of concept of uTREAT® in treating non-small cell lung cancer (NSCLC). Today's news follows the announcement earlier this year of positive preclinical results of uTREAT® in glioblastoma. Data from the study showed that uTREAT®, when administered to a preclinical mouse model of non-small cell lung cancer (NSCLC), effectively inhibited tumor growth.

This data demonstrates the potential for uTREAT® to be used as a radioligand therapy for the treatment of NSCLC and supports further development for this indication. Curasight's uPAR theranostic platform is based on two-pronged approach to enable better and more targeted cancer detection and treatment. Using intelligent cancer imaging with uTRACE® platform the company can more accurately detect and classified certain cancers.

This understanding can then be utilised with uTREAT® platform to provide more targeted and gentle treatment for certain cancers.